Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3)

被引：0
|
作者：
Piha-Paul, Sarina A.
Call, Justin A.
Spira, Alexander I.
Bartolome, Jorge
de Miguel, Maria J.
Du, Yangchun
DiLea, Clifford
Panchabhai, Sonali
Lakhani, Nehal J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[2] START Mt Reg, West Valley City, UT USA
[3] NEXT Oncol Virginia, Fairfax, VA USA
[4] UTEC Hosp Clin San Carlos, Madrid, Spain
[5] START Madrid CIOCC, Madrid, Spain
[6] Mural Oncol, Waltham, MA USA
[7] START Midwest, Grand Rapids, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2587
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study
    Chiorean, E. G.
    Sweeney, C. J.
    Verschraegen, C. F.
    Lee, F. C.
    Jones, S. F.
    Rabinowitz, I.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
    Rosen, Lee S.
    Bello, Carlo L.
    Mulay, Marilyn
    Dinolfo, Melissa
    Baum, Charles
    CANCER RESEARCH, 2006, 66 (08)
  • [43] Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts.
    Lotze, Michael T.
    Appleman, Leonard Joseph
    Ramanathan, Ramesh K.
    Tolcher, Anthony W.
    Beeram, Muralidhar
    Papadopoulos, Kyriakos P.
    Rasco, Drew Warren
    Weiss, Glen J.
    Mountz, James M.
    Toledo, Frederico G. S.
    Alvarez, Rene J.
    Oborski, Matthew J.
    Rajagopalan, Prabhu
    Jeffers, Michael
    Roth, Diane
    Dubowy, Ronald L.
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
    Janku, Filip
    Elez, Elena
    Iyer, Gopa
    Yamamoto, Noboru
    Tan, Daniel Shao-Weng
    Stathis, Anastasios
    Stammberger, Uz M.
    Evans, Helen
    Seroutou, Abdelkader
    Mais, Anna
    Schuler, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Phase I study of NX211 given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients (pts) with solid tumors - an NCIC Clinical Trials Group study.
    Gelmon, KA
    Eisenhauer, E
    Reyno, L
    Fisher, B
    Ayers, D
    Lee, U
    Hirte, H
    D'Aloisio, S
    Hurak, S
    Hamilton, M
    Ptaszynski, M
    Onetto, N
    CLINICAL CANCER RESEARCH, 1999, 5 : 3794S - 3794S
  • [46] A phase I dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion twice-weekly during a 3-week cycle in patients (pts) with refractory solid tumors
    Isambert, N.
    Spitaleri, G.
    Fumoleau, P.
    Noberasco, C.
    Ramazeilles, C.
    Chadjaa, M.
    Bolloni, L.
    De Braud, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors
    Wainberg, Z.
    Tabernero, J.
    Maqueda, M. A.
    Leong, S.
    Del Conte, G.
    Britten, C.
    Brega, N.
    Davis, C.
    Houk, B.
    Pierce, K.
    Vermette, J.
    Siu, L.
    Brana, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 171 - 171
  • [48] A phase-I dose-escalation study of SR271425 administered intravenously in split doses (d1-d2d3) in patients with refractory solid tumors
    Fumoleau, P
    Campone, M
    Isambert, N
    Maury, S
    Monin-Baroille, P
    Bourbouloux, E
    Schackleton, G
    de Braud, F
    Berille, J
    Dujardin, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 224S - 224S
  • [49] Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).
    Rosen, Ezra
    Silverman, Ian M.
    Fontana, Elisa
    Lee, Elizabeth Katherine
    Spigel, David R.
    Hojgaard, Martin
    Lheureux, Stephanie
    Mettu, Niharika B.
    Carneiro, Benedito A.
    Carter, Louise
    Plummer, Elizabeth Ruth
    Schonhoft, Joseph D.
    Ulanet, Danielle
    Manley, Peter
    Reis-Filho, Jorge S.
    Xu, Yi
    Rimkunas, Victoria
    Koehler, Maria
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
    Colombo, Ilaria
    Genta, Sofia
    Martorana, Federica
    Guidi, Monia
    Frattini, Milo
    Samartzis, Eleftherios Pierre
    Brandt, Simone
    Gaggetta, Sheila
    Moser, Laura
    Pascale, Mariarosa
    Terrot, Tatiana
    Sessa, Cristiana
    Stathis, Anastasios
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 5012 - 5019
12345